PMC5223353_01
Representative CT scan images of target lesions showing response to dabrafenib monotherapy and dabrafenib and trametinib combination. Patient started treatment and showed response at the first 3 monthly CT scan (b, f) in all target lesions compared to the baseline (a, e). At the second 3 monthly CT scan the pelvic mass showed increased size (panel
c, indicated by straight red line) compared to baseline while pulmonary metastases showed maintained response (panel
g, representative image). Introduction of trametinib halted further progression of the pelvic mass (panel
d) and induced further regression of the pulmonary metastases (panel
h) suggesting that MEK inhibition can synergize and revert resistance to BRAF targeting agents in endometrial cancer harboring BRAF V600F mutation
40164_2016_61_Fig1_HTML.jpg
PMC5223353_01_40164_2016_61_Fig1_HTML.jpg
Fig1
A gradual interval increase in the size of the lung metastases and the left pelvic sidewall mass was observed on 8 weekly CT scans, meeting the criteria of disease progression by RECIST 1.1 after 5 cycles of treatment (Fig. 1a, e).  A CT scan performed after the initial 3 months of treatment showed reduction in size of all the lung metastases and the left pelvic soft tissue mass (Fig. 1b, f). Subsequent CT scan performed after an additional 3 months of dabafenib monotherapy showed continued response of the lung metastases (Fig. 1g), but slight increase of the size of the pelvic mass (Fig. 1c). A re-staging CT scan performed after 3 months of combination treatment showing maintained response of the lung metastases and stable size of pelvic mass (Fig. 1d, h).